Objective: To describe the current use of treatments to prevent or treat patent ductus arteriosus (PDA) in preterm infants, examine the association between different treatment strategies and neonatal outcomes and review the variation in these practices between centers.
Introduction
Many infants born at less than 28 weeks gestation will have persistent patency of the ductus arteriosus and will be assigned the diagnosis of a patent ductus arteriosus (PDA) at some time during the early neonatal period. A PDA is associated with serious neonatal morbidities, including necrotizing enterocolitis (NEC) 1 and chronic lung disease (CLD). 2, 3 Although a cause and effect relationship between a PDA and these morbidities has not been established, many neonatologists administer indomethacin prophylactically to prevent intraventricular hemorrhage (IVH), with the additional benefit of reducing the incidence of a symptomatic PDA. 4 Indomethacin treatment is also used beyond the first day of life (DOL) to effect closure of PDAs that are either identified on echocardiogram or by physical examination, particularly those that are associated with signs and symptoms (i.e. symptomatic PDAs). A minority of infants with a diagnosis of a PDA undergo surgical ligation, most commonly when medical therapy fails.
These therapies are administered with the intent of reducing associated morbidity. However, there is little evidence to suggest that prevention or treatment of a PDA reduces the incidence of these morbidities, and treatment with indomethacin and surgical ligation is associated with serious adverse effects such as intestinal perforation [5] [6] [7] and vocal cord paralysis. 8 Therefore, although these therapies are common, their use remains a source of continued debate. 9 We describe the current use of treatments to prevent or treat the PDA in preterm infants receiving care from a national consortium of neonatal care providers. We examine the association between different treatment strategies and neonatal outcome and review the variation in these practices between centers. This information will be helpful when designing randomized, controlled trials of management strategies of the PDA.
Materials and methods
Using a de-identified data set from which several other observations have been published, 10, 11 we assembled a retrospective cohort of neonates for this study. Clinical data on these neonates were recorded during their hospitalization in the NICU. Admission, discharge and daily progress notes were generated with a proprietary computer-assisted tool and their data stored in an electronic database. Pediatrix Medical Group provides intensive care services in 220 hospitals in 32 states and Puerto Rico, and added approximately 10 to 15 centers each year. The data in the electronic database are used for medical record documentation, billing and quality improvement projects. Clinicians providing care to patients interact with the patient's data on a daily basis to generate progress notes and billing. Each day's note is stored along with medications used and diagnoses made. There were no a priori definitions of diagnoses, clinicians coded them as they saw fit. The local data are consolidated within the Pediatrix Medical Group data warehouse, de-identified, made compliant with Health Insurance Portability and Accountability Act of 1996 (HIPPA) regulations and configured into tables that can be joined and queried for statistical analyses.
Neonates eligible for inclusion in the study were cared for in neonatal intensive care units managed by the Pediatrix Medical Group. From the Pediatrix Medical Group data warehouse, 10, 11 we identified infants born between 23 and 30 weeks gestation from January 1, 1997 to December 31, 2004. In the data warehouse, infants are included if they were discharged from a unit; this includes discharged to home, transferred to another institution or death. We reviewed data on clinical and demographic variables, including birth weight, estimated gestational age (EGA), gender, race and the use of indomethacin, report of a diagnosis of a PDA and/or surgical ligation of a PDA. The de-identified data set does not included data on how the diagnosis of a PDA was made or the echocardiographic findings in patients with a diagnosis. Similarly, there are no data on how the clinician made the decision to treat a PDA when it was first diagnosed. Because of the way data is recorded on medication use, we only evaluated the first course of therapy and were unable to obtain information on dose. 12 We did not evaluate the outcome of neonates exposed to multiple courses of indomethacin.
By reviewing the medications and diagnoses tables, we identified five distinct groups of patients defined by the report of a PDA and/or treatments to prevent or treat a PDA as follows:
1. Prophylactic indomethacin: Included infants who were first treated with indomethacin on DOL 0 or 1. We did not distinguish between the use of indomethacin for the prevention of IVH or for its use for prevention or treatment of a PDA. We examined each of these groups with respect to demographic characteristics, mortality and common neonatal morbidities, including CLD, NEC, intestinal perforation, retinopathy of prematurity (ROP) and IVH. CLD was defined as treatment with oxygen at discharge or at 36 weeks postmenstrual age, whichever occurred first. The case/operational definitions for the other morbidities are the same as those used for the Vermont-Oxford Network and confirmed by periodic audits. In addition, we examined the incidence of ligation in the prophylactic and the indicated indomethacin treatment groups. We determined the postnatal age at which initial treatments were administered and changes in utilization of treatment strategies during the study period. We also evaluated site variability in the use of strategies. In the site-specific analysis, we used data from sites caring for at least 20 gestational age eligible infants during the study period.
Permission to conduct the analysis without written informed consent was provided by the University of North Carolina at Chapel Hill Biomedical Institutional Review Board.
Statistics
The median, range and quartiles were calculated when the data were not normally distributed. We compared the differences between treatment groups using univariate and multivariate techniques. Continuous variables (EGA and birth weight) were evaluated with one-way analysis of variance (ANOVA) to look for differences across all treatment groups. When differences were identified by ANOVA, two-tailed Student's t-tests were used to evaluate each possible two-group comparison. Categorical variables (e.g., race and gender) were evaluated with a two-tailed w 2 test and Fisher's exact test. Non-parametric continuous data were assessed with a Kruskal-Wallis ANOVA. After univariate analysis, we used multivariate logistic regression to calculate the adjusted OR for Treatment of patent ductus arteriosus in preterm infants M Laughon et al death and morbidity between two groups (indicated treatment vs PDA without treatment). In the logistic regression analysis, we incorporated the variables found by univariate analysis to be a P<0.1. Birth weight and gestational age were entered into the model as continuous variables and included in all models even if the two groups being compared were statistically similar for these two variables. Cases with missing values for any of the independent variables were excluded from the analysis. All statistical analysis was done using JMP Release 5.0.1a (SAS Institute Inc, Cary, NC, USA).
Results
During the study period, 34 602 gestational age eligible infants were identified from 162 sites; these infants were the cohort for this study (see Figure 1 ). Among these infants, 6189 (18%) patients received prophylactic indomethacin treatment, 5690 (16%) patients received indicated indomethacin treatment, 3886 (11%) patients had a diagnosis of PDA without treatment, and 702 (2%) patients received ligation only. No patients received ibuprofen. In the indicated treatment group, 5639/5690 (99%) patients had a report of a PDA diagnosis and a report of indomethacin treatment and 51 (1%) had a report of treatment with indomethacin but no report of a PDA as a diagnosis. There were 18 136 (52%) patients in whom there was no PDA. There was little change in the proportion of patients in any of the assigned treatment groups over time (Figure 2 ), except the proportion of patients with no PDA decreased from 59% in 1997 to 49% in 2004.
The demographic features of each group are presented in Table 1 . Infants who received prophylactic indomethacin were less mature when compared with infants who received indicated treatment or had a PDA without treatment. Infants in the ligation-only group were smaller, less mature and more often out-born compared with infants in all of the other groups. Infants with no PDA were more mature, larger, had higher Apgar scores and less often required assisted ventilation during the first 2 days after birth. Infants who received indicated indomethacin treatment had similar demographics (gestational age, birth weight, gender, maternal race and Apgar scores) compared with infants who had a PDA without treatment.
The differences in percentage in each treatment group by gestational age are presented in Figure 3 . The incidence of prophylactic indomethacin was highest in the lowest gestational ages, ranging from 26% of infants at 23 weeks to 6% at 30 weeks. The incidence of ligation only was also highest at the lowest gestational ages, ranging from 7% of infants at 23 weeks to less than 1% at 29 and 30 weeks.
The timing of treatment with indomethacin and PDA ligation is presented in Figure 4 . The proportion of infants receiving indomethacin treatment at each postnatal age relative to the total number of infants receiving this treatment as either prophylactic or indicated treatment is depicted in this figure. Over 50% of all infants treated with indomethacin were treated prophylactically. The incidence of indicated indomethacin treatment peaked on DOL 2 and then declined over the first week of life. In the analysis of the timing of PDA ligations, the total number of infants ligated, irrespective of whether they had received prior indomethacin treatment, was used as the denominator to calculate proportions at each postnatal age. A small proportion of infants were ligated during the first 2 days of life; the peak occurrence was on DOL 3. Fifty percent of ligations occurred by DOL 4. The figure depicts a peak after DOL 21, reflecting the cumulative incidence of later ligations.
The mortality and morbidities of infants by group are presented in Table 2 . We expressed mortality as both overall mortality and mortality among infants who survived for more than 2 and 7 days. Infants who were ligated without indomethacin had a higher incidence of mortality at all time points (range 12 to 14%), PDA, no treatment n =3886 (11%) Figure 1 Derivation of study groups. Figure 2 The proportion of infants in the cohort by year in the prophylactic indomethacin treatment group, indicated indomethacin treatment group, ligation-only group , no PDA group and a PDA without treatment group. The numbers do not add up to 100% because of rounding.
Treatment of patent ductus arteriosus in preterm infants M Laughon et al whereas infants with no PDA had the lowest mortality after 2 days of age (5%). Among survivors at 2 days of age, infants who had a PDA without treatment had a lower incidence of CLD when compared with infants who received prophylactic or indicated treatment (34 vs 41% and 42%, respectively). The incidences of NEC and severe IVH (grade III or IV) were similar among infants who received prophylactic indomethacin, infants who received indicated treatment and infants who had a PDA without treatment. Infants who received indicated treatment had a higher incidence of PDA ligation (18%) compared with infants who received prophylactic indomethacin (9%). Infants who had a PDA without treatment had a lower incidence of severe ROP and intestinal perforation compared with infants in the indomethacin treatment groups.
We performed a multivariate analysis to calculate the adjusted ORs for the comparison of outcomes between the PDA without treatment group and the indicated indomethacin treatment group. Other groups were not evaluated in this comparison because they represent distinct populations in terms of birth weight and maturity, and include other potential biases of outcome. To permit more legitimate comparisons between groups, morbidities were calculated among survivors beyond 2 days of age. Birth weight, Figure 3 The proportion of infants by gestational age in the prophylactic indomethacin treatment group, indicated indomethacin treatment group, ligation-only group or PDA without treatment group.
Treatment of patent ductus arteriosus in preterm infants M Laughon et al EGA, inborn status and antenatal steroids were included in all of the models. In this analysis, mortality among survivors to 2 days of age was lower (OR 0.6, 95% CI 0.5 to 0.7, P<0.01) in the indicated treatment group compared with the PDA without treatment group. In these infants, the ORs for CLD, isolated intestinal perforation and severe retinopathy (stages 3 and 4) were higher in the indicated treatment group compared to the PDA without treatment group (OR 1.5, 95% CI 1.3 to 1.6, P<0.01; OR 1.5, 95% CI 1.1 to 2.0, P<0.01 and 1.4, 95% CI 1.2 to 1.6, P<0.01, respectively). The difference in mortality narrowed when calculated for survivors to 7 days of age (OR 0.8, 95% CI 0.7 to 1.0, P ¼ 0.034). The risk of NEC and IVH were not different between groups.
There was a wide variation in the utilization of treatment strategy between sites. Figure 5a depicts the proportion of infants at each site receiving prophylactic indomethacin among all infants and Figure 5b depicts the proportion of infants at each site receiving indicated indomethacin treatment among infants with a PDA. The proportion of infants receiving prophylactic indomethacin among all infants varied by site from 0 to 59% (median 9.5%). The proportion of infants receiving indicated treatment varied by site from 0 to 100% (median 62%).
Discussion
Our descriptive study reports recent trends in the management of the PDA in a large consortium of neonatal care providers. Abbreviations: CLD, chronic lung disease; DOL, day of life; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity; PDA, patent ductus arteriosus. a Ten patients died on day of treatment. b P<0.05; w 2 test followed by Fisher's exact test; the incidence of morbidities uses survivors to 2 days as the denominator.
c Oxygen therapy at 36 weeks PMA.
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Treatments that were evaluated included prophylactic indomethacin, indomethacin administered after the first 2 days of life and surgical ligation. As reported by others, in our cohort, infants with a lower gestational age were more likely to receive indomethacin, either prophylactically or as a treatment for an existing PDA, and were more likely to undergo ligation without prior treatment with indomethacin. 13 It is likely that the relatively high rate of prophylactic indomethacin among the least mature infants was motivated by the potential for reducing the likelihood of severe IVH rather than prevention of a PDA. There did not appear to be a substantial change in the relative utilization of this treatment strategy during the 8-year study period.
Ligation without prior indomethacin treatment occurred almost exclusively in infants born at less than 27 weeks gestation. Infants without a PDA were larger and more mature, and were less likely to be supported with mechanical ventilation in the early neonatal period. These groups represent demographically distinct groups. This observation is important and demonstrates the complexity of evaluating the outcomes of neonates with and without a PDA, and the effect of ligation on outcomes in any retrospective review where the 'size and severity of a PDA' are not assessed.
We examined mortality and a variety of morbidities between groups of infants defined by treatments to prevent or close a PDA. We presume that these outcomes to a great extent reflect risks, and thus inherent biases, imposed by the demography of each group. For example, infants had to survive the first 2 days of life to be eligible for indicated treatment. In the PDA without treatment group, it is likely that some infants died without treatment for a PDA because a choice was made not to deliver intensive care (including treatment for a PDA). In addition, mortality, IVH, ROP and CLD were most common in the ligation-only group, in which infants were the smallest and least mature compared with all other groups. Conversely, the group of infants without a PDA, in which infants were the largest and most mature, had the lowest rate of mortality and these morbidities.
Two groups had similar baseline characteristics, the group comprised infants who received indicated indomethacin treatment and the group of infants with a PDA that was not treated. Mortality was increased among infants with an untreated PDA, with an absolute risk difference of 2% between the two groups. This difference narrowed for mortality after 7 days of age. There were also differences in three other outcomes between these groups: an absolute difference in the occurrence of CLD of 8%, of ROP of 4% and intestinal perforation of 1% in infants with PDAs who were not treated, having lower event rates compared with neonates in the indicated treatment group.
Because this was not a randomized trial, inclusion in a group may have been influenced by a number of factors that might also have influenced the likelihood of these outcomes. The decision not to treat a PDA may have resulted from the presence of a PDA in critically ill infants in whom aggressive care was considered futile, and who subsequently died. Conversely, treatment may have been withheld in infants who had mild illness and were less likely to develop morbidities or in infants who had smaller PDAs and less left to right shunting of blood into the lung. An alternate explanation is that treatment with indomethacin contributes directly to selected morbidities as has been suggested for intestinal perforation. 5, 7, 14 There was wide variability across sites in the utilization of strategies to prevent or treat a PDA. Prophylactic indomethacin was used in up to 59% of infants in some centers, suggesting that all infants in these centers below a relatively advanced gestational age are treated in this manner. Conversely, in other centers prophylactic indomethacin was never used. The use of indicated treatment was equally variable. In some centers, 100% of infants with a PDA were treated and in other centers none of the infants with a PDA were treated with indomethacin. (a) The proportion of infants receiving prophylactic indomethacin treatment during the study period, expressed as a percentage of all infants in the cohort at that site. We used data from sites reporting at least 20 gestational age eligible infants during the study period. Sites reporting fewer than 20 study eligible patients were excluded. (b) The proportion of infants receiving indicated indomethacin treatment expressed as a percentage of all candidates for treatment (the total of all infants in the indicated indomethacin treatment group plus infants in the PDA without treatment group). We used data from sites reporting at least 20 gestational age eligible infants during the study period. Sites reporting fewer than 20 study eligible patients were excluded.
This variability could not be explained on the basis of differences in gestational age or birth weight distributions in the site populations. These observations suggest that there is no universally accepted standard of care for the prevention or treatment of the PDA, and that non-treatment is an option exercised in some centers.
There are a number of limitations of this study that impact the ability to draw inferences. The diagnosis of a PDA was not based on a uniform operational definition and may have depended upon the decision to collect diagnostic information (e.g. an echocardiogram). The decision to treat a PDA, and therefore inclusion in a treatment group was not random. It was made on the basis of clinician discretion, and our data demonstrate wide variability in practice. Although multivariate analytic techniques help compensate for imbalances between groups, only factors that are known to impact outcome and were available in the data set could be entered in the model. Therefore, this study, and virtually all observational studies, is more likely to generate questions and hypotheses than to provide conclusive results.
Conclusions
Treatments to prevent or close a PDA are used commonly, but the selection of infants for treatment and the decision of when and how to treat vary widely between centers. Based on comparisons of outcomes between groups of infants treated with different strategies for prevention or closure, including groups of infants who were untreated, this study provides no definitive evidence that any strategy improves outcome. Our findings suggest the need for randomized, placebo-controlled trials of the effect of treatment of the PDA in preterm infants. Ideally, there would be no crossover in the placebo group in these trials. Given the results of this study, we feel that this is an acceptable option.
